CYRX CryoPort, Inc. Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
20:12
03 авг
03 авг
The author describes being stopped out of an overweight SPY short while longs underperformed.
The author describes being stopped out of an overweight SPY short while longs underperformed, attributing the rally to a cap-weighted oversold bounce and signaling measured caution without new directional calls.
Низ.
15:21
07 июл
07 июл
Minervini flags CYRX as one of his worst-performing current open positions in a rotational.
Minervini flags CYRX as one of his worst-performing current open positions in a rotational market environment.
Низ.
17:46
30 июн
30 июн
The author reports daily performance of stocks on a focus list without stating any.
The author reports daily performance of stocks on a focus list without stating any forward-looking position or trade idea.
Низ.
22:16
07 мая
07 мая
Cryoport supports 766 clinical trials and 21 commercial therapies with >70% market share in cell/gene therapy cold chain. FDA regulatory moat due to integration into therapy filings. Pivoted to high-margin platform model after offloading courier to DHL. As CGT therapies scale and fertility preservation demand grows (Cryostork), the recurring revenue model becomes a compounding growth story. The stock is still below 2021 hype levels despite fundamentals improving. Cryoport is the infrastructure backbone for a nascent but exploding therapy class, with a regulatory lock-in that competitors cannot easily replicate. Slower-than-expected CGT adoption; regulatory changes; competition from UPS cold chain or in-house logistics.
Выс.
Об аналитическом покрытии CYRX
Buzzberg отслеживает CYRX (CryoPort, Inc.) в 2 источниках. Бычьих сигналов: 1, медвежьих: 0, от 2 аналитиков. Сентимент преимущественно бычий (25%). Всего отслеживаются 4 торговые идеи. Последние спикеры: Mark Minervini, u/Frosty-Revolution212.